Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with Plasmodium falciparum or P. vivax either alone or mixed~* Age \>12 months~* Weight \>5kg~* Living in the study clusters~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Anaemia, defined as Hb \<9g/dl~* G6PD deficiency (as determined by FST)~* Pregnant women as determined by Urine β-HCG pregnancy test~* Known hypersensitivity to any of the drugs given

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primaquine supervised (Type: ACTIVE_COMPARATOR): 14 days of supervised primaquine treatment (0.5mg/kg/day).
- Primaquine unsupervised (Type: ACTIVE_COMPARATOR): 14 days of unsupervised primaquine treatment (0.5mg/kg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).